Altre lingue Recursion Pharmaceuticals, Inc.

Azioni

RXRX

US75629V1044

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:08 17/05/2024			Variaz. 5gg	Var. 1 gen.
9,415 ^USD	-1,00%		+9,48%	-4,51%

13/05	Recursion Pharmaceuticals dichiara completato il supercomputer di intelligenza artificiale BioHive-2	MT
10/05	La perdita Q1 di Recursion Pharmaceuticals si allarga, ma le entrate aumentano	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Recursion Pharmaceuticals Says BioHive-2 AI Supercomputer Completed	13/05
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry	13/05
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry	13/05
Recursion Pharmaceuticals Q1 Loss Widens, Revenue Rises	10/05
Recursion Pharmaceuticals: Q1 Earnings Snapshot	09/05
Earnings Flash (RXRX) RECURSION PHARMACEUTICALS Reports Q1 Revenue $13.8M, vs. Street Est of $12.7M	09/05
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results	09/05
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9	02/05
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9	02/05
Recursion to Participate in Upcoming Investor Conferences	01/05
Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program	30/04
Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing	18/04
Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer	16/04
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer	16/04
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer	16/04
Recursion Appoints Najat Khan as Chief R&D Officer and Chief Commercial Officer	16/04
Recursion to Participate in Upcoming Investor Conference	02/04
Recursion to Participate in Upcoming Investor Conference	02/04
Recursion Publishes Annual Environmental, Social and Governance Report	26/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Recursion Pharmaceuticals, Inc.

Azioni

RXRX

US75629V1044

Altre lingue

Filtri